The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

Prehospital hypoxia, hypotension, and hypocarbia each were associated with poor outcomes after traumatic brain injury, ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

A grant from the Alzheimer’s Foundation of America will be used to purchase equipment to serve families affected by ...

2024 — The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

VERO BEACH — The Alzheimer’s Foundation of America has awarded a grant to the Alzheimer & Parkinson Association of Indian River County to expand its Project Lifesaver program, which provides ...